Home/Pipeline/Metabolite Delivery Platform (Therapeutic Programs)

Metabolite Delivery Platform (Therapeutic Programs)

Inflammatory Bowel Disease (IBD)

Pre-clinicalPlatform Development

Key Facts

Indication
Inflammatory Bowel Disease (IBD)
Phase
Pre-clinical
Status
Platform Development
Company

About ClostraBio

ClostraBio is focused on restoring intestinal barrier-protective function and innate immunity to maintain gut health and treat diseases of the gut and food allergy. The company leverages a well-rounded team of scientists and entrepreneurs with expertise in microbiology and bioengineering to develop both a dietary supplement and a versatile delivery platform. Their core technology aims to transform intestinal health through targeted metabolite delivery, addressing significant unmet needs in the IBD and food allergy markets.

View full company profile

About ClostraBio

ClostraBio is focused on restoring intestinal barrier-protective function and innate immunity to maintain gut health and treat diseases of the gut and food allergy. The company leverages a well-rounded team of scientists and entrepreneurs with expertise in microbiology and bioengineering to develop both a dietary supplement and a versatile delivery platform. Their core technology aims to transform intestinal health through targeted metabolite delivery, addressing significant unmet needs in the IBD and food allergy markets.

View full company profile

Other Inflammatory Bowel Disease (IBD) Drugs

DrugCompanyPhase
DFTX-201Definium TherapeuticsPreclinical
COSMO-232Cosmo PharmaceuticalsPreclinical
TamuzimodVentyx BiosciencesPhase 2
VTX958Ventyx BiosciencesPhase 2
GPR35 AgonistNxera PharmaPreclinical
SL-325Shattuck LabsPhase 2
SL-425Shattuck LabsPhase 1
ABS-101AbSciPre-clinical
ABO21009AboleIIs PharmaPhase 1